Faculty: Laszlo Endrenyi, PhD

Laszlo Endrenyi, PhDLaszlo Endrenyi, PhD
Professor Emeritus

General Research Area: Biological Model Building
Assessment of Bioavailability and Bioavailability of Drugs 


Selected Publications:

Aklillu E, Kalow W, Endrenyi L, Harper P, Miura J, Ozdemir V. CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet Genomics. 2007 Nov; 17(11):989-93.

L. Endrenyi, L. Tothfalusi. Evaluation of bioequivalence for highly variable drugs. In: Generic Drug Product Development, I. Kanfer and L. Shargel, eds., Taylor & Francis, New York, 2007; pp. 95-120. 

Tothfalusi L, Speidl S, Endrenyi L. Exposure-response analysis reveals that clinically important toxicity difference can exist between bioequivalent carbamazepine tablets. Br J Clin Pharmacol. 2008 Jan; 65(1):110-22. Epub 2007 Aug 15.  

Albers LJ, Ozdemir V, Marder SR, Raggi MA, Aravagiri M, Endrenyi L, Reist C. Low-dose fluvoxamine as an adjunct to reduce olanzapine therapeutic dose requirements: a prospective dose-adjusted drug interaction strategy. J Clin Psychopharmacol. 2005 Apr; 25(2):170-4. 

Tothfalusi L, Endrenyi L. Estimation of Cmax and Tmax in populations after single and multiple drug administrations. J Pharmacokinet Pharmacodyn. 2003 Oct; 30(5):363-85. 

Tothfalusi L, Endrenyi L, Midha KK. Scaling or wider bioequivalence limits for highly variable drugs and for the special case of C(max). Int J Clin Pharmacol Ther. 2003 May;41(5):217-25. 

Tothfalusi L, Endrenyi L. Limits for the scaled average bioequivalence of highly variable drugs and drug products. Pharm Res. 2003 Mar; 20(3):382-9. 

Tothfalusi L, Endrenyi L, Midha KK, Rawson MJ, Hubbard JW. Evaluation of the bioequivalence of highly-variable drugs and drug products. Pharm Res. 2001 Jun;18(6):728-33. 

Contact Information:
Department of Pharmacology and Toxicology
Email: l.endrenyi@utoronto.ca

Back to Top